Development of a target concentration intervention to individualize paroxysmal nocturnal hemoglobinuria treatment with pegcetacoplan
Annals of Hematology · 2024
DOI: 10.1007/s00277-024-05699-8 ↗Kurz gefasst
Klinische Studie in der Zeitschrift Annals of Hematology, 2024. Verfasst von Mendy Ter Avest und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Radboud University Medical Centre, P.O. Box 9101, Nijmegen, 6500 HB, The Netherlands. mendy.teravest@radboudumc.nl. Hauptthemen laut MEDLINE: Hemoglobinuria, Paroxysmal, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Pegcetacoplan (Aspaveli®/Empaveli™) is a factor C3 inhibitor that is approved for the treatment of paroxysmal nocturnal hemoglobinuria. An individualized dosing strategy might be useful to improve patient-friendliness and cost-effectiveness of this very expensive drug. Therefore, the aim of this study was to develop an individualized treatment regimen for pegcetacoplan based on the pharmacokinetic-pharmacodynamic data of the manufacturer. We conducted a clinical trial simulation with the approved dosing regimen of 1080 mg twice-weekly and a target concentration intervention-based dosing regimen in patients with and without prior eculizumab use. For eculizumab-naïve patients, the target concentration intervention-based dosing regimen resulted in a comparable fraction of patients with LDH normalization (LDH < 226 U/L) and hemoglobulin normalization (> 12 g/dL) compared to the approved regimen (LDH 50.2% and 50.0% respectively and hemoglobulin 45.6% and 44.4%). A modest dose reduction of ~ 5% was possible with target concentration intervention-based dosing. An intensified dosing interval was necessary in 2.3% of the patients however an interval prolongation was possible in 28.2% of the patients. Similar results were obtained for patients prior treated with eculizumab. In this study we show the potential of an individualized dosing regimen of pegcetacoplan with can improve patient friendliness in approximately 30% of the patients and improve therapy in approximately 2% of the patients at slightly reduced costs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Radboud University Medical Centre, P.O. Box 9101, Nijmegen, 6500 HB, The Netherlands. mendy.teravest@radboudumc.nl.
- Department of Hematology, Radboud University Medical Centre, Nijmegen, The Netherlands.
- Department of Pediatric Nephrology, Radboud University Medical Centre, Nijmegen, The Netherlands.
- Department of Pharmacy, Radboud University Medical Centre, P.O. Box 9101, Nijmegen, 6500 HB, The Netherlands.
Zitieren
APA
Ter Avest, M., Langemeijer, S. M. C., Blijlevens, N. M. A., van de Kar, N. C. A. J., & Ter Heine, R. (2024). Development of a target concentration intervention to individualize paroxysmal nocturnal hemoglobinuria treatment with pegcetacoplan. Annals of Hematology. https://doi.org/10.1007/s00277-024-05699-8
Vancouver
Ter Avest M, Langemeijer SMC, Blijlevens NMA, van de Kar NCAJ, Ter Heine R. Development of a target concentration intervention to individualize paroxysmal nocturnal hemoglobinuria treatment with pegcetacoplan. Annals of Hematology. 2024. doi:10.1007/s00277-024-05699-8
BibTeX
@article{TerAvest2024,
author = {Ter Avest, Mendy and Langemeijer, Saskia M C and Blijlevens, Nicole M A and van de Kar, Nicole C A J and Ter Heine, Rob},
title = {Development of a target concentration intervention to individualize paroxysmal nocturnal hemoglobinuria treatment with pegcetacoplan},
journal = {Annals of Hematology},
year = {2024},
doi = {10.1007/s00277-024-05699-8}
}
EUVIMED